Prestige Consumer Healthcare Inc. $PBH Shares Acquired by Campbell & CO Investment Adviser LLC

Key Points

• Campbell & CO Investment Adviser LLC increased its stake in Prestige Consumer Healthcare by 38.9%, acquiring an additional 6,054 shares to own a total of 21,619 shares, valued at approximately $1.86 million.
• Prestige Consumer Healthcare's quarterly earnings report showed earnings per share (EPS) of $0.95, missing estimates of $1.01, with revenue down 6.6% year-over-year.
• Analysts have mixed ratings on the stock, with three recommending a Buy and three suggesting a Hold, reflecting a consensus rating of "Moderate Buy" and an average price target of $93.33.

Campbell & CO Investment Adviser LLC grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 38.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,619 shares of the company's stock after purchasing an additional 6,054 shares during the period. Campbell & CO Investment Adviser LLC's holdings in Prestige Consumer Healthcare were worth $1,859,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. CW Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 10.1% in the 1st quarter. CW Advisors LLC now owns 162,656 shares of the company's stock valued at $13,983,000 after buying an additional 14,941 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Prestige Consumer Healthcare by 2.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 466,204 shares of the company's stock valued at $40,081,000 after acquiring an additional 11,112 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Prestige Consumer Healthcare by 4.8% in the 1st quarter. Northern Trust Corp now owns 852,274 shares of the company's stock valued at $73,270,000 after acquiring an additional 39,198 shares during the last quarter. Versor Investments LP purchased a new position in shares of Prestige Consumer Healthcare in the 1st quarter valued at about $714,000. Finally, Raymond James Financial Inc. boosted its position in shares of Prestige Consumer Healthcare by 4.2% in the 1st quarter. Raymond James Financial Inc. now owns 568,178 shares of the company's stock valued at $48,846,000 after purchasing an additional 22,738 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

NYSE PBH traded up $0.41 during mid-day trading on Thursday, hitting $67.37. The stock had a trading volume of 676,013 shares, compared to its average volume of 602,764. Prestige Consumer Healthcare Inc. has a 52-week low of $62.95 and a 52-week high of $90.04. The company has a market cap of $3.32 billion, a price-to-earnings ratio of 15.81, a P/E/G ratio of 2.11 and a beta of 0.43. The company has a 50 day simple moving average of $73.94 and a 200 day simple moving average of $80.70. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million for the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business's quarterly revenue was down 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on PBH shares. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.